InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
5
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
+10.0%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Schimmel Paul, Director. Director active across 2 companies, notably aTYR PHARMA INC. Aggregated, 7 disclosures have been logged. Breakdown: 5 buys · 0 sell. Total volume traded: €2.9m. Activity tracked since 18 May 2021. The latest transaction was disclosed on 8 October 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Schimmel Paul
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
682,001 shares@ US$0.898100.0% of flowCommon StockSEC:0001193125-25-236131:0
Canonical exit: 6 Jan 2026 (T+90)
41,052 shares@ US$1.74172.6% of flowCommon StockSEC:0000950170-24-086159:0
Canonical exit: 20 Oct 2024 (T+90)
200,000 shares@ US$2.2516.3% of flowCommon StockSEC:0001209191-23-028607:0
Canonical exit: 8 Aug 2023 (T+90)
6,000 sharesCommon stockSEC:0001209191-23-026067:0
250,000 shares@ US$8.0072.8% of flowCommon StockSEC:0001209191-21-057339:0
Canonical exit: 19 Dec 2021 (T+90)
50,000 shares@ US$3.986.9% of flowCommon StockSEC:0001209191-21-034293:0
Canonical exit: 16 Aug 2021 (T+90)
11,925 sharesCommon StockSEC:0001209191-16-094247:0
7 of 7 declarations
About Schimmel Paul
Paul Schimmel is a Board Member at aTYR Pharma Inc. He plays a key role in the governance of the company, contributing to strategic decision-making and overseeing operations. His experience in the pharmaceutical sector allows him to provide valuable insights to the board.
